Comprehensive and authoritative, Opioid Receptors and Antagonists: From Bench to Clinic offers neuroscientists, pharmacologists and interested clinicians a unique survey of the extensive and diverse research efforts currently employed with opioid antagonists to develop novel innovative drug therapies. Summarizes the present understanding of the chemistry, pharmacology and molecular biology of opioid receptors and their subtypes Highlights differences and similarities between the opioid pharmacology of animals and human Describes current and potential therapeutic areas for opioid antagonists, including substance abuse, alcohol and ingestive behaviors, behavioral disorders and other medical indications, supported by nonclinical and clinical evidence Focuses on the development of exciting and innovative drug delivery approaches that are being used with opioid antagonists for the above medical indications

Held at Boppard, Germany, October 3-6, 1984

Examine the strong evidence of this unrealized pain management tool Cholecystokinin (CCK), the regulatory peptide hormone found primarily in the gastrointestinal tract that works as a neurotransmitter throughout the nervous system, has been researched for years. CCK antagonists in conjunction with opioids are beginning to be seen as having possible major therapeutic benefits in pain management. Cholecystokinin and Its Antagonists in Pain Management is an extensive examination that gathers the mounting compelling evidence into one comprehensive source. Here researchers, neuroscientists, physicians, and pharmacy professionals are given the research and findings they need to explore the possible applications of CCK antagonists for a variety of illnesses. Cholecystokinin and Its Antagonists in Pain Management extensively describes opioids in pain management, CCK and the body’s uses for the chemical, CCK receptor antagonists, and the evidence that points to its being a possible breakthrough application in pain management. Various animal studies are offered that present a convincing view of what may be the future of chronic pain management, with less side effects and a reduction in analgesic tolerance than when opioids are used alone. Potential uses of CCK antagonists are clearly discussed. The book is comprehensively referenced and provides several tables and graphs to fully illustrate the research findings. Topics in Cholecystokinin and Its Antagonists in Pain Management include: in vivo localization of CCK CCK as a gut and nervous system peptide factors that increase CCK anti-opioid effects CCK receptor antagonists pro-analgesic effect of CCK antagonists CCK antagonists reducing analgesic tolerance to opioids safety of combining opioids and CCK antagonists human clinical application of CCK antagonists Cholecystokinin and Its Antagonists in Pain Management is a crucial source of the latest information and research results on CCK that is certain to be important for neuroscientists, clinicians, and pharmaceutical industry professionals.

5-Hydroxytryptamine-3 Receptor Antagonists provides a comprehensive, authoritative review of the topic featuring contributions by recognized leaders in the field. The book's three sections cover compound discovery and activity rationalization, the use of compounds for studying 5-HT3 receptors, and their applications to therapeutics. This book will be an important reference for oncologists, researchers working with the CNS and gastrointestinal disorders, and anyone working in the 5-HT field within the pharmaceutical arena, academia, and medical practice.